- Home
- PAM vs MMED Comparison
PAM vs MMED Comparison
Compare PAM & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAM | MMED |
|---|---|---|
| Founded | 1945 | 1983 |
| Country | Argentina | United States |
| Employees | 1847 | 2800 |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.3B |
| IPO Year | N/A | 2026 |
Fundamental Metrics
Financial Performance| Metric | PAM | MMED |
|---|---|---|
| Price | $86.42 | $16.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $94.50 | $22.56 |
| AVG Volume (30 Days) | 135.1K | ★ 1.2M |
| Earning Date | 05-06-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $204,770.38 | $15.99 |
| Revenue Next Year | $16.65 | $10.00 |
| P/E Ratio | $13.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.95 | $10.65 |
| 52 Week High | $94.50 | $17.86 |
Technical Indicators
Market Signals| Indicator | PAM | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 55.58 | 63.33 |
| Support Level | $79.02 | $14.70 |
| Resistance Level | $89.52 | N/A |
| Average True Range (ATR) | 2.46 | 0.90 |
| MACD | 0.64 | 0.04 |
| Stochastic Oscillator | 59.01 | 73.31 |
Price Performance
Historical ComparisonAbout PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business, mainly in oil and gas production and power generation. The firm's operating business segments are Oil and Gas, Generation, Petrochemicals, Holding, Transportation, and Others. The company derives the maximum revenue from the oil and gas segment.
About MMED MiniMed Group Inc. Common Stock
Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.